id	author	title	date	pages	extension	mime	words	sentence	flesch	summary	cache	txt
dpc-4893	Fratton, Zeno; Maione, Vincenzo; Bighetti, Stefano; Bettolini, Luca; Stinco, Giuseppe; Errichetti, Enzo	Real-life Experience of Bimekizumab in 27 Obese Patients With Plaque-type Psoriasis: a 24-week Multicenter Retrospective Study	2025	3	.pdf	application/pdf	1480	85	56	Obesity affects around 25% of psoriasis patients and is often associated with poorer responses to biologic therapies, especially TNF-α and interleukin (IL)-17-inhibitors [1-5].1-4 Bimekizumab (BKZ), a monoclonal antibody targeting both IL-17A and IL-17F, has shown promising results in the treatment of moderate to se- vere psoriasis in both clinical trials and real-world studies [6], yet specific data in obese patients are scarce. Case Presentation This 24-week retrospective study, conducted at 2 Italian der- matological centers (Udine and Brescia), aims to evaluate the efficacy and safety of BKZ in obese patients with plaque-type psoriasis.	cache/dpc-4893.pdf	txt/dpc-4893.txt